Stanford University


Showing 201-210 of 7,777 Results

  • Timothy Angelotti MD, PhD

    Timothy Angelotti MD, PhD

    Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine

    Current Research and Scholarly InterestsMy research efforts are focused on investigating the pharmacological and physiological interface of the autonomic nervous system with effector organs. Utilizing molecular, cellular, and electrophysiological techniques, we are examining alpha2 adrenergic receptor function in cultured sympathetic neurons. Future research aims will be directed toward understanding neurotransmitter release in general.

  • Martin S. Angst

    Martin S. Angst

    Professor of Anesthesiology, Perioperative and Pain Medicine (MSD)

    Current Research and Scholarly InterestsOur laboratory studies biological and clinical determinants of human resilience using surgery as an injury model.

  • Subini Ancy Annamma

    Subini Ancy Annamma

    Associate Professor of Education

    BioPrior to her doctoral studies, Subini Ancy Annamma was a special education teacher in both public schools and youth prisons. Currently, she is an Associate Professor in the Graduate School of Education at Stanford University. Her research critically examines the ways students are criminalized and resist that criminalization through the mutually constitutive nature of racism and ableism, how they interlock with other marginalizing oppressions, and how these intersections impact youth education trajectories in urban schools and youth prisons. Further, she positions students as knowledge generators, exploring how their narratives can inform teacher and special education. Dr. Annamma’s book, The Pedagogy of Pathologization (Routledge, 2018) focuses on the education trajectories of incarcerated disabled girls of color and has won the 2019 AESA Critic’s Choice Book Award & 2018 NWSA Alison Piepmeier Book Prize. Dr. Annamma is a past Ford Postdoctoral Fellow, AERA Division G Early Career Awardee, Critical Race Studies in Education Associate Emerging Scholar recipient, Western Social Science Association's Outstanding Emerging Scholar, and AERA Minority Dissertation Awardee. Dr. Annamma’s work has been published in scholarly journals such as Educational Researcher, Teachers College Record, Review of Research in Education, Teaching and Teacher Education, Theory Into Practice, Race Ethnicity and Education, Qualitative Inquiry, among others.

  • Justin P. Annes M.D., Ph.D.

    Justin P. Annes M.D., Ph.D.

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders

    DIABETES
    The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.

    (1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.

    (2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.

    HEREDIATY PARAGAGLIOMA SYNDROME
    The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.

    As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.

  • Arash Anoshiravani

    Arash Anoshiravani

    Clinical Professor, Pediatrics - Adolescent Medicine

    Current Research and Scholarly InterestsResearch interests include high-risk youth, adolescent health services, and the juvenile justice system.

  • David Ansel

    David Ansel

    Clinical Associate Professor, Developmental-Behavioral Pediatrics

    BioI graduated from UCLA (now Geffen) School of Medicine, did my pediatrics residency at Columbia-Presbyterian in NYC, followed by a clinical fellowship in developmental (what was then called an “ambulatory”) pediatrics at Boston Children’s Hospital. The first 28 years of my career were spent in clinical practice combining both DBP and primary care (the latter focused on serving CSHCN). During those years I was involved in numerous divide-bridging efforts - including programs to coordinate inpatient & outpatient medicine, connect tertiary & primary care, and promote teamwork between pediatricians, psychologists, nurse practitioners, and other community partners. I founded my own solo practice in 1989 and managed its growth to an 8-provider group over the next 25 years. Our practice was a founding member of the PPOC and I served on its board of directors for 6 years. The PPOC is one of the largest pediatric IPA’s in the country, with >200 member providers affiliated with Boston Children's Hospital. Over the years we were involved in groundbreaking QI initiatives including those involving asthma, weight, and ADHD management; medical home; and behavioral health integration with primary care.

    I’m now well into my career's “second act” on the clinician-educator track here at Stanford. I'm proud to have piloted our division's primary care initiative (DBPCI) and am now in the process of planning for a second phase thereof, hoping to make improved collaboration between DBP and primary care more available to more patients. I also pioneered the use of telehealth in our division, and then helped guide its sudden widespread adoption by my peers during the COVID-19 crises. Looking forward, I expect what we have learned during the pandemic will inform what we do for DBPCI 2.0.

  • anthony lising antonio

    anthony lising antonio

    Associate Professor of Education

    Current Research and Scholarly InterestsTransitions to postsecondary education; racial, ethnic, and religious minority college student development.